{"id":"https://openalex.org/W2023580320","doi":"https://doi.org/10.1067/mcp.2002.121788","title":"Low daily 10\u2010mg and 20\u2010mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)","display_name":"Low daily 10\u2010mg and 20\u2010mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)","publication_year":2002,"publication_date":"2002-03-01","ids":{"openalex":"https://openalex.org/W2023580320","doi":"https://doi.org/10.1067/mcp.2002.121788","mag":"2023580320","pmid":"https://pubmed.ncbi.nlm.nih.gov/11907488"},"language":"en","primary_location":{"id":"doi:10.1067/mcp.2002.121788","doi":"https://doi.org/10.1067/mcp.2002.121788","is_oa":false,"landing_page_url":"https://doi.org/10.1067/mcp.2002.121788","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036502026","display_name":"Magnus Christensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":true,"raw_author_name":"Magnus Christensen","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038555087","display_name":"Gunnel Tybring","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Gunnel Tybring","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007504265","display_name":"Kazuo Mihara","orcid":"https://orcid.org/0000-0002-2990-3874","observed_orcids":["https://orcid.org/0000-0002-2990-3874"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Kazuo Mihara","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059863447","display_name":"Norio Yasui\u2010Furokori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Norio Yasui\u2010Furokori","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016907727","display_name":"Juan Antonio Carrillo","orcid":"https://orcid.org/0000-0002-1288-120X","observed_orcids":["https://orcid.org/0000-0002-1288-120X"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Juan Antonio Carrillo","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090808679","display_name":"Sara Ramos","orcid":"https://orcid.org/0000-0001-7696-9908","observed_orcids":["https://orcid.org/0000-0001-7696-9908"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Sara I. Ramos","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103686397","display_name":"Katarina Andersson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Katarina Andersson","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001100678","display_name":"Marja\u00ad\u2010Liisa Dahl","orcid":"https://orcid.org/0000-0002-4837-6299","observed_orcids":["https://orcid.org/0000-0002-4837-6299"]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Marja\u2010Liisa Dahl","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111567063","display_name":"Leif Bertilsson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I28166907","display_name":"Karolinska Institutet","ror":"https://ror.org/056d84691","country_code":"SE","type":"education","lineage":["https://openalex.org/I28166907"]},{"id":"https://openalex.org/I80606768","display_name":"Universidad de Extremadura","ror":"https://ror.org/0174shg90","country_code":"ES","type":"education","lineage":["https://openalex.org/I80606768"]}],"countries":["ES","SE"],"is_corresponding":false,"raw_author_name":"Leif Bertilsson","raw_affiliation_strings":["Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","Department of Pharmacology, Medical School University of Extremadura Badajoz Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology at Karolinska Institutet Huddinge University Hospital Stockholm Sweden","institution_ids":["https://openalex.org/I28166907"]},{"raw_affiliation_string":"Department of Pharmacology, Medical School University of Extremadura Badajoz Spain","institution_ids":["https://openalex.org/I80606768"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5036502026"],"corresponding_institution_ids":["https://openalex.org/I28166907","https://openalex.org/I80606768"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":5.6967,"has_fulltext":false,"cited_by_count":90,"citation_normalized_percentile":{"value":0.95943145,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"71","issue":"3","first_page":"141","last_page":"152"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":1.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11264","display_name":"Coffee research and impacts","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluvoxamine","display_name":"fluvoxamine","score":0.9819999933242798},{"id":"https://openalex.org/keywords/cyp1a2-inhibition","display_name":"CYP1A2 inhibition","score":0.8339999914169312},{"id":"https://openalex.org/keywords/cyp2c19-inhibition","display_name":"CYP2C19 inhibition","score":0.9990000128746033},{"id":"https://openalex.org/keywords/caffeine-metabolism","display_name":"caffeine metabolism","score":0.7620000243186951},{"id":"https://openalex.org/keywords/cytochrome-p450","display_name":"cytochrome P450","score":0.734000027179718},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.597000002861023},{"id":"https://openalex.org/keywords/cyp2d6-polymorphism","display_name":"CYP2D6 polymorphism","score":0.8069999814033508},{"id":"https://openalex.org/keywords/debrisoquine","display_name":"debrisoquine","score":0.7450000047683716},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.4830000102519989},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.4959999918937683}],"concepts":[{"id":"https://openalex.org/C2777498785","wikidata":"https://www.wikidata.org/wiki/Q422210","display_name":"Omeprazole","level":2,"score":0.8762988448143005},{"id":"https://openalex.org/C2778500429","wikidata":"https://www.wikidata.org/wiki/Q60235","display_name":"Caffeine","level":2,"score":0.7595601081848145},{"id":"https://openalex.org/C2780768313","wikidata":"https://www.wikidata.org/wiki/Q408068","display_name":"Cytochrome","level":3,"score":0.7513184547424316},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6436854600906372},{"id":"https://openalex.org/C2779910183","wikidata":"https://www.wikidata.org/wiki/Q409236","display_name":"Fluvoxamine","level":5,"score":0.6420682668685913},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6414464712142944},{"id":"https://openalex.org/C86745063","wikidata":"https://www.wikidata.org/wiki/Q3737406","display_name":"CYP1A2","level":4,"score":0.6097819805145264},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.4900625944137573},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.42861688137054443},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.23596182465553284},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.21922534704208374},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.20417636632919312},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.1875878870487213},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.10770383477210999},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.099139004945755},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08027368783950806}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000697","descriptor_name":"Central Nervous System Stimulants","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D002110","descriptor_name":"Caffeine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D003647","descriptor_name":"Debrisoquin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009853","descriptor_name":"Omeprazole","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009853","descriptor_name":"Omeprazole","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D009853","descriptor_name":"Omeprazole","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018663","descriptor_name":"Adrenergic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065609","descriptor_name":"Cytochrome P-450 CYP1A2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1067/mcp.2002.121788","doi":"https://doi.org/10.1067/mcp.2002.121788","is_oa":false,"landing_page_url":"https://doi.org/10.1067/mcp.2002.121788","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology &amp; Therapeutics","raw_type":"journal-article"},{"id":"pmid:11907488","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11907488","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G141588184","display_name":"Pharmacogenetics of human cytochromes P450","funder_award_id":"R01GM060548","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"},{"id":"https://openalex.org/G439462472","display_name":null,"funder_award_id":"1-R01 GM 60548-01A2","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"}],"funders":[{"id":"https://openalex.org/F4320337354","display_name":"National Institute of General Medical Sciences","ror":"https://ror.org/04q48ey07"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1985137752","https://openalex.org/W4231410666","https://openalex.org/W2087863011","https://openalex.org/W2060473370","https://openalex.org/W2003197532","https://openalex.org/W1969652902","https://openalex.org/W2090628258","https://openalex.org/W2273600806","https://openalex.org/W2046107045","https://openalex.org/W2039848755"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Fluvoxamine":[1],"is":[2,398,421],"metabolized":[3],"by":[4,113,187],"the":[5,12,87,144,150,213,216,220,250,275,278,296,313,323,329,370,381,403,442],"polymorphic":[6],"cytochrome":[7],"P450":[8],"(CYP)":[9],"2D6":[10],"and":[11,22,32,41,46,70,80,91,105,126,136,167,182,192,205,272,318,347,366,432],"smoking-inducible":[13],"CYP1A2.":[14],"Therapeutic":[15],"doses":[16,53,65],"of":[17,36,54,66,83,89,99,116,119,147,159,178,197,212,224,264,306,316,341,361,369,388,405,419,428,445,466],"fluvoxamine":[18,55,100,198,258,317,362,420,446],"inhibit":[19,56],"both":[20,270,364,429],"CYP1A2":[21,57,90,271],"CYP2C19.":[23,61],"In":[24],"this":[25],"study":[26,151],"we":[27],"used":[28],"extensive":[29],"metabolizers":[30,34],"(EMs)":[31],"poor":[33],"(PMs)":[35],"debrisoquin":[37,84],"(INN,":[38],"debrisoquine)":[39],"(CYP2D6)":[40],"two":[42],"probes,":[43],"caffeine":[44,69,307,430],"(CYP1A2)":[45,431],"omeprazole":[47,73,137,433],"(CYP2C19),":[48],"to":[49,77,85,103,108,124,131,165,172,267,291,302,336,384,410,423,440],"investigate":[50],"whether":[51],"nontherapeutic":[52,415],"but":[58,218],"possibly":[59],"not":[60,200,219,438],"METHODS:":[62],"Single":[63],"oral":[64,97,210,359,416],"100":[67],"mg":[68,72,102,107,121,128,162,169,252,281,460],"20":[71],"were":[74,140,185,199],"given":[75],"separately":[76],"5":[78,81],"EMs":[79,125,166,204,234],"PMs":[82,104,173,206,231],"assess":[86],"activity":[88],"CYP2C19,":[92,273],"respectively.":[93,351],"Initially,":[94],"a":[95,156,208,226,261,356,376,425,453],"single":[96,209,365],"dose":[98,158,211,223,259,287,315,418,456],"(25":[101],"50":[106],"EMs)":[109],"was":[110,153,235,288,394,437],"given,":[111],"followed":[112],"1":[114,130,171,175,254,283,462],"week":[115],"daily":[117,417,455],"administration":[118],"25":[120,127,251],"x":[122,129,163,170,253,256,282,285,461,464],"2":[123,164,257,286,465],"PMs.":[132],"Caffeine":[133],"(day":[134,138],"6)":[135],"7)":[139],"again":[141],"administered":[142],"at":[143],"steady":[145,248],"state":[146],"fluvoxamine.":[148,389,406,467],"Later":[149],"protocol":[152],"repeated":[154],"with":[155,233],"lower":[157,221,228,279,324],"fluvoxamine,":[160,179,225],"10":[161,168,280,459],"for":[174,269,402],"week.":[176],"Concentrations":[177],"caffeine,":[180],"omeprazole,":[181],"their":[183],"metabolites":[184],"analyzed":[186],"HPLC":[188],"methods":[189],"in":[190,203,230,380],"plasma":[191,297,330],"urine.":[193],"RESULTS:":[194],"The":[195,293,326],"kinetics":[196],"significantly":[201,227],"different":[202],"after":[207,277,312,322,363,451],"drug.":[214,371],"At":[215,247],"higher":[217,314],"steady-state":[222],"clearance":[229,360],"compared":[232],"observed":[236],"(geometric":[237],"mean,":[238],"0.86":[239],"versus":[240],"1.4":[241],"L/h":[242],"per":[243],"kilogram;":[244],"P":[245],"<.05).":[246],"state,":[249],"or":[255,284,463],"caused":[260],"pronounced":[262],"inhibition":[263,276,427],"about":[265,289],"75%":[266],"80%":[268],"whereas":[274],"40%":[290],"50%.":[292],"area":[294,327],"under":[295,328],"concentration-versus-time":[298],"curve":[299,332],"from":[300,333],"0":[301],"24":[303],"hours":[304,338],"[AUC(0-24)]":[305],"increased":[308,386],"5-fold":[309],"(P":[310,320,345,349],"<.001)":[311,346],"2-fold":[319],"<.05)":[321],"dose.":[325],"concentration-time":[331],"time":[334],"zero":[335],"8":[337],"[AUC(0-8)]":[339],"ratio":[340],"5-hydroxyomeprazole/omeprazole":[342],"decreased":[343],"3.4-fold":[344],"2.4-fold":[348],"<.001),":[350],"One":[352],"EM":[353],"subject":[354,373],"had":[355],"very":[357],"low":[358,454],"multiple":[367],"dosing":[368],"This":[372],"might":[374],"have":[375],"deficient":[377],"transporter":[378],"protein":[379],"gut,":[382],"leading":[383],"an":[385,399],"absorption":[387],"CONCLUSION:":[390],"No":[391],"convincing":[392],"evidence":[393],"found":[395],"that":[396],"CYP2D6":[397],"important":[400],"enzyme":[401],"disposition":[404],"Other":[407],"factors":[408],"seem":[409],"be":[411],"more":[412],"important.":[413],"A":[414],"sufficient":[422],"provide":[424],"marked":[426],"(CYP2C19)":[434],"metabolism.":[435],"It":[436],"possible":[439],"separate":[441],"inhibitory":[443],"effects":[444],"on":[447],"these":[448],"enzymes,":[449],"even":[450],"such":[452,457],"as":[458]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}